1 hour ago
1
jetcityimage/iStock Editorial via Getty Images
Eli Lilly (NYSE:LLY) announced on Tuesday that its oral weight loss therapy, orforglipron, reached the main goals in a second Phase 3 trial, allowing the company to move forward with global regulatory submissions for the once-daily GLP-1 receptor agonist.
Citing
© FBT Company 2025. All rights are reserved
English (US) ·